{{Drugbox
| drug_name = 
| IUPAC_name        = ''N''-(3-<nowiki/>{3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2''H'')-yl}phenyl)acetamide
| image             = Trametinib.svg
| alt               = 
| caption           = 

<!-- Clinical data -->
| tradename         = Mekinist 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = D 
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = Rx-only
| legal_status      = 
| routes_of_administration = 

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 

<!-- Identifiers -->
| CAS_number        = 871700-17-3
| ATCvet            = 
| ATC_prefix        = L01
| ATC_suffix        = XE25
| PubChem           = 11707110
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 33E86K87QN
| DrugBank          = 
| ChemSpiderID      = 9881833
| ChEMBL = 2103875
| ChEBI             = 75998
| synonyms          = GSK1120212
| KEGG = D10175

<!-- Chemical data -->
| C=26 | H=23 | F=1 | I=1 | N=5 | O=4
| molecular_weight  = 615.39 g/mol
| smiles            = Ic1ccc(c(F)c1)N\C3=C\2/C(=O)N(C(=O)N(C/2=C(\C(=O)N3C)C)c4cccc(NC(=O)C)c4)C5CC5
| StdInChI = 1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
| StdInChIKey          = LIRYPHYGHXZJBZ-UHFFFAOYSA-N
}}

'''Trametinib''' (trade name '''Mekinist''') is a cancer drug.  It is a [[MEK inhibitor]] drug with anti-cancer activity.<ref name=nci>[http://www.cancer.gov/drugdictionary?cdrid=599034 Trametinib], NCI Drug Dictionary</ref>

It inhibits [[MEK1]] and [[MEK2]].<ref name=nci/>

Trametinib had good results for metastatic [[melanoma]] carrying the [[BRAF (gene)|BRAF]] [[V600E]] mutation in a phase III clinical trial. In this mutation, the amino acid [[valine]] (V) at position 600 within the BRAF protein has become replaced by [[glutamic acid]] (E) making the mutant BRAF protein constitutively active.<ref>[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=96304 METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).]</ref>

In May 2013, trametinib was approved as a single-agent by the [[Food and Drug Administration]] for the treatment of patients with V600E mutated metastatic melanoma.<ref>{{cite news | url = https://www.reuters.com/article/2013/05/30/us-glaxosmithkline-approvals-idUSBRE94S1A020130530 | title = GSK melanoma drugs add to tally of U.S. drug approvals | publisher = Reuters | date = May 30, 2013}}</ref> 
Clinical trial data demonstrated that resistance to single-agent trametinib often occurs within 6 to 7 months.<ref name="NEJM">{{cite journal | url = http://www.nejm.org/doi/full/10.1056/NEJMoa1210093 | title = Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations | publisher = New England Journal of Medicine | date = November 1, 2012 | doi=10.1056/NEJMoa1210093 | pmid=23020132 | pmc=3549295 | volume=367 | issue=18 | pages=1694â€“703}}</ref> To overcome this, trametinib was combined with the [[BRAF (gene) | BRAF]] inhibitor [[dabrafenib]].<ref name="NEJM" /> As a result of this research, on January 8, 2014, the FDA approved the combination of dabrafenib and trametinib for the treatment of patients with BRAF V600E/K-mutant metastatic melanoma.<ref>{{cite news | url = http://www.onclive.com/web-exclusives/FDA-Approves-First-Ever-Combination-for-Metastatic-Melanoma | title = Dabrafenib/Trametinib Combination Approved for Advanced Melanoma | publisher = OncLive | date = January 9, 2014}}</ref>

==References==
{{reflist}}

{{Extracellular chemotherapeutic agents}}

[[Category:Cancer treatments]]
[[Category:Cyclopropanes]]
[[Category:Fluoroarenes]]
[[Category:Iodoarenes]]
[[Category:Acetanilides]]
[[Category:MEK inhibitor]]

{{antineoplastic-drug-stub}}